Interactions
| ID | Title | drug 1 Sort descending | drug 1 dose | drug 1 effect | drug 2 | drug 2 dose | drug 2 effect | Clinical Effects | Color | Clinical Bottom Line | Management | Alt Agents | Info Source | Edit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6868 | Lenacapavir Flibanserin | Lenacapavir | Flibanserin | Potential increased risk of GI adverse effects, insomnia, dry mouth, tachycardia |
Red: Avoid combination | Do not coadminster: potentially increased levels of flibanserin | Use alternative agents. |
DHHS Adult ARV Guidelines | ||||||
| 6884 | Lenacapavir Mometasone | Lenacapavir | Mometasone | Potential increased risk of corticosteroid adverse effects (e.g. Cushing's syndrome and adrenal supression). |
Yellow: Adjust dosing | Minimal data to guide interaction: weigh risks and benefits of using this combination | If coadministering, initiate lowest starting dose and titrate to clinical effect. Monitor for adverse effects such as adrenal insufficiency and Cushing's syndrome. |
Sunlenca Product Label | ||||||
| 6900 | Lenacapavir Quinidine | Lenacapavir | Quinidine | Potential increased risk of quinidine adverse effects |
Red: Avoid combination | Do not coadminister: potentially increased levels of quinidine | Use alternative agents. |
DHHS Adult ARV Guidelines | ||||||
| 6916 | Lenacapavir Tramadol | Lenacapavir | Tramadol | Increased risk of tramadol adverse effects |
Yellow: Adjust dosing | Minimal data to guide interaction: weigh risks and benefits of using this combination | If coadministering, consider decreasing tramadol dose when coadministering. Titrate to clinical effect and monitor for sedation. |
DHHS Adult ARV Guidelines | ||||||
| 6837 | Lenacapavir Buprenorphine | Lenacapavir | Buprenorphine / naloxone | Unknown effect on buprenorphine |
Yellow: Adjust dosing | Minimal data to guide interaction: weigh risks and benefits of using this combination | If initiating buprenorphine in a person already on lenacapavir, start with lowest feasible dose and titrate to clinical effect. If initiating lenacapavir in a person stable on buprenorphine, dose adjustment of buprenorphine may be required. Monitor for clinical efficacy and adverse effects (e.g. sedation, respiratory depression). |
DHHS Adult ARV Guidelines | ||||||
| 6853 | Lenacapavir Diltiazem | Lenacapavir | Diltiazem | Potential increased risk of diltiazem adverse effects |
Yellow: Adjust dosing | Minimal data to guide interaction: weigh risks and benefits of using this combination | If coadministering, monitor for cardiac medication adverse effects (e.g. hypotension) |
DHHS Adult ARV Guidelines | ||||||
| 6869 | Lenacapavir Fluticasone | Lenacapavir | Fluticasone | Potential increased risk of corticosteroid adverse effects (e.g. Cushing's syndrome and adrenal supression). |
Yellow: Adjust dosing | Minimal data to guide interaction: weigh risks and benefits of using this combination | If coadministering, initiate lowest starting dose and titrate to clinical effect. Monitor for adverse effects such as adrenal insufficiency and Cushing's syndrome. |
Sunlenca Product Label | ||||||
| 6885 | Lenacapavir Naloxegol | Lenacapavir | Naloxegol | Increased risk of naloxegol adverse effects |
Yellow: Adjust dosing | Minimal data to guide interaction: risks likely to outweigh benefits | Consider using alternative agents. If coadministration is unavoidable, decrease dose of naloxegol and monitor for adverse reactions. |
Sunlenca Product Label | ||||||
| 6901 | Lenacapavir Ranolazine | Lenacapavir | Ranolazine | Potential increased risk of ranolazine adverse effects |
Yellow: Adjust dosing | Minimal data to guide interaction: weigh risks and benefits of using this combination | If coadministering, do not exceed ranolazine dose of 500 mg twice daily. |
Sunlenca Product Label | ||||||
| 6917 | Lenacapavir Trazodone | Lenacapavir | Trazodone | Potential increased risk of trazodone adverse effects (e.g. sedation, CNS effects) |
Yellow: Adjust dosing | Minimal data to guide interaction: weigh risks and benefits of using this combination | If coadministering start with lowest dose and titrate to clinical effect. Monitor for trazodone-related adverse events. |
DHHS Adult ARV Guidelines | ||||||
| 6935 | Rilpivirine (IM) Sildenafil | Rilpivirine (IM) | Sildenafil | Green: Administer standard doses | Administer standard doses | |||||||||
| 6951 | Rilpivirine (IM) Clarithromycin | Rilpivirine (IM) | Clarithromycin | Potential for increased rilpivirine concentrations |
Orange: Minimal data to guide interaction | Minimal data to guide interaction: weigh risks and benefits of using this combination | Consider alternative agents. If coadministration is necessary, monitor for adverse effects |
|||||||
| 6936 | Rilpivirine (IM) Chlorzoxazone | Rilpivirine (IM) | Chlorzoxazone | Green: Administer standard doses | Administer standard doses | |||||||||
| 6952 | Rilpivirine (IM) Erythromycin | Rilpivirine (IM) | Erythromycin | Potential for increased rilpivirine concentrations |
Orange: Minimal data to guide interaction | Minimal data to guide interaction: weigh risks and benefits of using this combination | Consider alternative agents. If coadministration is necessary, monitor for adverse effects |
|||||||
| 6937 | Rilpivirine (IM) SOF | Rilpivirine (IM) | Sofosbuvir | Green: Administer standard doses | Administer standard doses | |||||||||
| 6953 | Rilpivirine (IM) Acetaminophen | Rilpivirine (IM) | Acetaminophen | Green: Administer standard doses | Administer standard doses | |||||||||
| 6938 | Rilpivirine (IM) Famotidine | Rilpivirine (IM) | Famotidine | Green: Administer standard doses | Administer standard doses | |||||||||
| 6954 | Rilpivirine (IM) Darunavir/ritonavir | Rilpivirine (IM) | Darunavir, Ritonavir | Green: Administer standard doses | Administer standard doses | |||||||||
| 6939 | Rilpivirine (IM) SOF/VEL | Rilpivirine (IM) | Sofosbuvir / Velpatasvir | Green: Administer standard doses | Administer standard doses | |||||||||
| 6955 | Rilpivirine (IM) Raltegravir | Rilpivirine (IM) | Raltegravir | Green: Administer standard doses | Administer standard doses | |||||||||
| 6940 | Rilpivirine (IM) CBZ | Rilpivirine (IM) | Carbamazepine | Decreased rilpivirine effects |
Red: Avoid combination | Do not coadminister: Potential for reduced levels of rilpivirine | Use alternative agents |
|||||||
| 6956 | Rilpivirine (IM) Tenofovir disoproxil fumarate | Rilpivirine (IM) | Tenofovir Disoproxil Fumarate | Green: Administer standard doses | Administer standard doses | |||||||||
| 6941 | Rilpivirine (IM) Oxcarbazepine | Rilpivirine (IM) | Oxcarbazepine | Decreased rilpivirine effects |
Red: Avoid combination | Do not coadminister: Potential for reduced levels of rilpivirine | Use alternative agents |
|||||||
| 6957 | Rilpivirine (IM) Digoxin | Rilpivirine (IM) | Digoxin | Green: Administer standard doses | Administer standard doses | |||||||||
| 6942 | Rilpivirine (IM) St. John's Wort (Hypericum perforatum) | Rilpivirine (IM) | St. John's Wort | Decreased rilpivirine effects |
Red: Avoid combination | Do not coadminister: Potential for reduced levels of rilpivirine | Use alternative agents |
|||||||
| 6958 | Rilpivirine (IM) Metformin | Rilpivirine (IM) | Metformin | Green: Administer standard doses | Administer standard doses | |||||||||
| 6943 | Rilpivirine (IM) RPT | Rilpivirine (IM) | Rifapentine | Decreased rilpivirine effects |
Red: Avoid combination | Do not coadminister: Potential for reduced levels of rilpivirine | Use alternative agents |
|||||||
| 6944 | Rilpivirine (IM) Omeprazole | Rilpivirine (IM) | Omeprazole | Green: Administer standard doses | Administer standard doses | |||||||||
| 6929 | Rilpivirine (IM) Methadone | Rilpivirine (IM) | Methadone | Potential for reduced methadone concentrations |
Orange: Minimal data to guide interaction | Minimal data to guide interaction: weigh risks and benefits of using this combination | If coadministering, monitor for methadone efficacy |
|||||||
| 6945 | Rilpivirine (IM) RIF | Rilpivirine (IM) | Rifampin | Decreased rilpivirine effects |
Red: Avoid combination | Do not coadminister: Potential for reduced levels of rilpivirine | Use alternative agents |
|||||||
| 6930 | Rilpivirine (IM) Aluminum and magnesium hydroxide antacid | Rilpivirine (IM) | Aluminum and magnesium hydroxide antacid | Green: Administer standard doses | Administer standard doses | |||||||||
| 6946 | Rilpivirine (IM) RFB | Rilpivirine (IM) | Rifabutin | Decreased rilpivirine effects |
Red: Avoid combination | Do not coadminister: Potential for reduced levels of rilpivirine | Use alternative agents |
|||||||
| 6931 | Rilpivirine (IM) Ketoconazole | Rilpivirine (IM) | Ketoconazole | Potential for increased rilpivirine concentrations |
Orange: Minimal data to guide interaction | Minimal data to guide interaction: weigh risks and benefits of using this combination | If coadministering, use standard doses and consider monitoring for antifungal efficacy and QTc prolongation |
|||||||
| 6947 | Rilpivirine (IM) Phenobarbital | Rilpivirine (IM) | Phenobarbital | Decreased rilpivirine effects |
Red: Avoid combination | Do not coadminister: Potential for reduced levels of rilpivirine | Use alternative agents |
|||||||
| 6932 | Rilpivirine (IM) Atorvastatin | Rilpivirine (IM) | Atorvastatin | Green: Administer standard doses | Administer standard doses | |||||||||
| 6948 | Rilpivirine (IM) Phenytoin | Rilpivirine (IM) | Phenytoin | Decreased rilpivirine effects |
Red: Avoid combination | Do not coadminister: Potential for reduced levels of rilpivirine | Use alternative agents |
|||||||
| 6933 | Rilpivirine (IM) DTG | Rilpivirine (IM) | Dolutegravir | Green: Administer standard doses | Administer standard doses | |||||||||
| 6949 | Rilpivirine (IM) Dexamethasone | Rilpivirine (IM) | Dexamethasone | Decreased rilpivirine effects if dexamethasone is given as more than a single-dose treatment |
Red: Avoid combination | Do not coadminister: Potential for reduced levels of rilpivirine | Use alternative agents if therapy requires more than a single dose treatment of dexamethasone. |
|||||||
| 6934 | Rilpivirine (IM) Ethinyl estradiol / Norethindrone acetate | Rilpivirine (IM) | Ethinyl estradiol / Norethindrone acetate | Green: Administer standard doses | Administer standard doses | |||||||||
| 6950 | Rilpivirine (IM) Azithromycin | Rilpivirine (IM) | Azithromycin | Potential for increased rilpivirine concentrations |
Orange: Minimal data to guide interaction | Minimal data to guide interaction: weigh risks and benefits of using this combination | Consider alternative agents. If coadministration is necessary, monitor for adverse effects |
